中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
4期
328-331
,共4页
王莉%范磊%缪扣荣%许戟%张闰%洪鸣%朱华渊%沈文怡%张晓艳
王莉%範磊%繆釦榮%許戟%張閏%洪鳴%硃華淵%瀋文怡%張曉豔
왕리%범뢰%무구영%허극%장윤%홍명%주화연%침문이%장효염
淋巴瘤%造血干细胞移植
淋巴瘤%造血榦細胞移植
림파류%조혈간세포이식
Lymphoma%Hematopoietic stem cell transplantation
目的 观察自体造血干细胞移植(ASCT)治疗恶性淋巴瘤的疗效.方法 回顾性分析1999年4月至2013年10月接受ASCT的81例恶性淋巴瘤患者的临床资料.其中非霍奇金淋巴瘤(NHL)70例,霍奇金淋巴瘤(HL)11例.外周血造血干细胞动员均采用大剂量依托泊苷联合G-CSF,预处理方案均为BEAM方案(卡莫司汀+阿糖胞苷+依托泊苷+马法兰).结果 所有患者均采集到足够的外周血造血干细胞.所有患者移植后均获得造血重建,中性粒细胞绝对值恢复至＞0.5×109/L的中位时间为10(7～16)d,血小板计数恢复至＞20×109/L的中位时间为10(6～17)d.中位随访23(2～139)个月,无进展生存(PFS)率为72.7％,总生存(OS)率为88.6％,中位PFS、OS时间均未达到.移植前患者是否达完全缓解为影响PFS的独立预后因素.无一例患者发生移植相关死亡.结论 ASCT是治疗恶性淋巴瘤安全、有效的方法.
目的 觀察自體造血榦細胞移植(ASCT)治療噁性淋巴瘤的療效.方法 迴顧性分析1999年4月至2013年10月接受ASCT的81例噁性淋巴瘤患者的臨床資料.其中非霍奇金淋巴瘤(NHL)70例,霍奇金淋巴瘤(HL)11例.外週血造血榦細胞動員均採用大劑量依託泊苷聯閤G-CSF,預處理方案均為BEAM方案(卡莫司汀+阿糖胞苷+依託泊苷+馬法蘭).結果 所有患者均採集到足夠的外週血造血榦細胞.所有患者移植後均穫得造血重建,中性粒細胞絕對值恢複至＞0.5×109/L的中位時間為10(7～16)d,血小闆計數恢複至＞20×109/L的中位時間為10(6～17)d.中位隨訪23(2～139)箇月,無進展生存(PFS)率為72.7％,總生存(OS)率為88.6％,中位PFS、OS時間均未達到.移植前患者是否達完全緩解為影響PFS的獨立預後因素.無一例患者髮生移植相關死亡.結論 ASCT是治療噁性淋巴瘤安全、有效的方法.
목적 관찰자체조혈간세포이식(ASCT)치료악성림파류적료효.방법 회고성분석1999년4월지2013년10월접수ASCT적81례악성림파류환자적림상자료.기중비곽기금림파류(NHL)70례,곽기금림파류(HL)11례.외주혈조혈간세포동원균채용대제량의탁박감연합G-CSF,예처리방안균위BEAM방안(잡막사정+아당포감+의탁박감+마법란).결과 소유환자균채집도족구적외주혈조혈간세포.소유환자이식후균획득조혈중건,중성립세포절대치회복지＞0.5×109/L적중위시간위10(7～16)d,혈소판계수회복지＞20×109/L적중위시간위10(6～17)d.중위수방23(2～139)개월,무진전생존(PFS)솔위72.7％,총생존(OS)솔위88.6％,중위PFS、OS시간균미체도.이식전환자시부체완전완해위영향PFS적독립예후인소.무일례환자발생이식상관사망.결론 ASCT시치료악성림파류안전、유효적방법.
Objective To investigated the curative effect of autologous hematopoietic stem cell transplantation (ASCT) for malignant lymphoma.Methods The clinical data of 81 patients with malignant lymphoma received ASCT from April 1999 to October 2013 were retrospectively analyzed.Of 81 patients,70 were non-Hodgkin's lymphoma (NHL) and 11 Hodgkin's lymphoma (HL).High dose of etoposide combined with G-CSF was used to mobilize peripheral hematopoietic stem cell.Preconditioning regimen was BEAM (carmustine + cytarabine + etoposide + melphalan).Results Enough peripheral blood stem cells were collected from all patients.All of the patients after transplantation achieved hematopoietic reconstitution,the median time of the absolute neutrophil count (ANC) recovery to ＞0.5 × 109/L time was 10 (7-16) d,and the median time of platelet count recovery to ＞20× 109/L was 10 (6-17) d.With the follow-up of 23 (2-139) months,progression free survival (PFS) was 72.7％,and overall survival (OS) was 88.6％.The median PFS and OS were not reached.Complete remission (CR) before ASCT was an independent prognostic factor of PFS.No transplant related death happened.Conclusion ASCT was a safe and effective method for treatment of malignant lymphoma.
